Loomis, Sayles & Company
NVAX icon

Loomis, Sayles & Company’s Novavax NVAX Stock Holding History

Loomis, Sayles & Company’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,183
Closed -$9K – 1022
2023
Q3 		$9K Buy
+1,183
New +$9.45K ﹤0.01% 812
2023
Q2 		– Sell
-763
Closed -$5K – 1043
2023
Q1 		$5K Buy
763
+638
+510% +$5.87K ﹤0.01% 913
2022
Q4 		$1K Buy
125
+98
+363% +$1.73K ﹤0.01% 841
2022
Q3 		$0 Hold
27
– – ﹤0.01% 1013
2022
Q2 		$1K Buy
+27
New +$1.4K ﹤0.01% 940

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company's NVAX Position: Q4 2023 in Review

Loomis, Sayles & Company sold out of Novavax (NVAX) in Q4 2023, closing a stake of 1,183 shares — an estimated $9K sold.

Loomis, Sayles & Company first reported a position in NVAX in Q2 2022 and held it in 5 quarters. The position peaked at $9K in Q3 2023. 199 funds tracked by Wall St. Rank hold NVAX as of Q4 2023.

  • Loomis, Sayles & Company reported no remaining Novavax position as of Q4 2023 after selling out during the quarter.
  • Loomis, Sayles & Company sold 1,183 Novavax shares in Q4 2023, an estimated $9K.
  • Loomis, Sayles & Company first reported a position in Novavax in Q2 2022 and held it in 5 quarters.
  • Loomis, Sayles & Company's Novavax position peaked at $9K in Q3 2023.
  • 199 funds tracked by Wall St. Rank held Novavax as of Q4 2023.

Based on Loomis, Sayles & Company's 13F filing for Q4 2023, filed 13 Feb 2024.